|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0001792,
umls-concept:C0003873,
umls-concept:C0008976,
umls-concept:C0030705,
umls-concept:C0717758,
umls-concept:C0720193,
umls-concept:C0871261,
umls-concept:C0936012,
umls-concept:C1274040,
umls-concept:C1514923,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C2911692
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2003-4-2
|
|
pubmed:abstractText |
Approximately 3% of the US population over the age of 65 years has rheumatoid arthritis (RA). We compared the safety and efficacy of etanercept (Enbrel) in patients with RA who were > or = 65 years to those < 65 years in open-label and double-blind, randomized clinical trials.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
0315-162X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
30
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
691-6
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:12672185-Age Factors,
pubmed-meshheading:12672185-Aged,
pubmed-meshheading:12672185-Antirheumatic Agents,
pubmed-meshheading:12672185-Female,
pubmed-meshheading:12672185-Humans,
pubmed-meshheading:12672185-Immunoglobulin G,
pubmed-meshheading:12672185-Male,
pubmed-meshheading:12672185-Middle Aged,
pubmed-meshheading:12672185-Randomized Controlled Trials as Topic,
pubmed-meshheading:12672185-Receptors, Tumor Necrosis Factor,
pubmed-meshheading:12672185-Retrospective Studies,
pubmed-meshheading:12672185-Treatment Outcome
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
Response to etanercept (Enbrel) in elderly patients with rheumatoid arthritis: a retrospective analysis of clinical trial results.
|
|
pubmed:affiliation |
University of Texas Southwestern Medical Center at Dallas, Dallas, TX, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
